Assess diffuse enlargement and focal nodules systematically, separate airway and cancer risk from thyroid function, and route ultrasound, scintigraphy and cytology through current UK pathways.
Thyroid enlargement spans physiological variation, autoimmune diffuse disease, multinodular hyperplasia, cysts, inflammatory lesions and neoplasia. A visible neck swelling may be clinically harmless, while a small posterior or substernal lesion can affect the recurrent laryngeal nerve or airway. History and examination therefore prioritise progression, compression and local invasion before cosmetic dimensions.
Ultrasound is the main structural risk tool when a nodule or gland abnormality has been appropriately identified. Composition, echogenicity, shape, margin, calcification, extrathyroidal extension and lymph-node appearance contribute to a standardised category. Vascularity alone is a weak malignancy discriminator. The 2026 UK consensus emphasises context-sensitive thresholds and multidisciplinary review rather than one rigid size rule applied to every U3, U4 or U5 lesion.
Function changes the diagnostic route. Low TSH prompts free hormones and scintigraphy through endocrine or nuclear medicine, because a hot focus rarely needs aspiration. Normal or high TSH leaves ultrasound-led risk stratification central. Cytology is reported in a Thy category and must be reconciled with clinical and sonographic risk; discordant or repeatedly non-diagnostic cases belong in a thyroid multidisciplinary team rather than a cycle of unplanned procedures.
Graves disease or autoimmune thyroiditis can enlarge the whole gland through receptor stimulation, inflammation or compensatory tissue change.
Clonal nodular growth, colloid accumulation and cystic degeneration commonly produce solitary or multinodular structural abnormalities, often with normal thyroid function.
Thyroiditis and thyroid neoplasia can present as focal or diffuse enlargement, particularly when pain, rapid growth, fixation or cervical nodes accompany the swelling.
Hyperplasia, inflammation, fluid accumulation or neoplastic growth increases gland volume and may create a palpable or imaging-detected nodule.
Some nodules produce thyroid hormone autonomously and suppress TSH, while many structural lesions remain non-functioning and biochemically silent.
Posterior, invasive or substernal growth can affect trachea, oesophagus, recurrent laryngeal nerve or cervical vessels despite modest visible enlargement.
A longstanding soft mobile nodule or symmetric goitre without growth, nodes, voice change or compression is lower risk, but still requires appropriate TSH and structural triage rather than visual reassurance alone.
Rapid or progressive growth, hard fixation, suspicious cervical nodes, persistent unexplained hoarseness, prior neck irradiation or a relevant familial syndrome should accelerate specialist and cancer-pathway assessment.
Stridor, orthopnoea, positional dyspnoea, dysphagia, facial plethora or venous distension on arm elevation suggests tracheal, oesophageal or thoracic inlet compromise and may require emergency care.
Sudden pain and enlargement may represent haemorrhage into a cyst or nodule, while fever and focal inflammatory signs raise abscess; airway effect determines urgency.
Suppressed TSH, palpitations and a focal hot area on scintigraphy define autonomy; examine for other nodules because structural risk may lie outside the functioning focus.
A diffuse firm gland can accompany autoimmune thyroiditis, whereas a smooth vascular goitre with bruit supports Graves; biochemical and antibody context refines the structural impression.
A lateral neck lump separate from the gland may be nodal disease from infection or malignancy; ultrasound defines its relationship and morphology.
A midline cystic lesion may move with swallowing or tongue protrusion but does not share the thyroid's biochemical or ultrasound pattern.
A tender painful gland with raised inflammatory markers and transient hormone release favours inflammatory enlargement rather than an asymptomatic nodule.
Rapid growth, fixation, hoarseness, suspicious ultrasound features or abnormal nodes increase concern and direct cytology through the specialist pathway.
Large, retrosternal or invasive disease can compress trachea or oesophagus, causing breathlessness, stridor, dysphagia or positional symptoms.
Posterior or malignant extension may impair vocal-cord movement, producing persistent hoarseness, ineffective cough and aspiration risk that requires prompt structural assessment.
Autonomous nodules can produce persistent thyroid hormone excess, increasing atrial fibrillation, heart failure and bone-loss risk.
TSH and scintigraphy describe hormone activity; ultrasound and cytology describe structural malignancy risk. One result cannot substitute automatically for the other.
Location beside the recurrent laryngeal nerve, trachea or thoracic inlet can make modest size clinically important, while a large superficial goitre may be asymptomatic.
Scanning nonspecific symptoms without a palpable or appropriately triaged structural indication finds incidental nodules and can create procedures without improving outcomes.
Colour flow can support functional impressions but is not a reliable standalone cancer discriminator; morphology and nodes carry more structured risk information.
Benign cytology is reassuring when it matches a low-risk lesion sampled correctly; a highly suspicious ultrasound with benign cells deserves multidisciplinary review, not automatic discharge.
Assuming a normal TSH proves a thyroid nodule is benign.
Sending a patient with stridor for routine outpatient imaging instead of airway escalation.
Requesting FNA before scintigraphy in a suppressed-TSH autonomous nodule pathway.
Applying a single size cutoff without ultrasound category, clinical risk or local consensus.
Calling repeated non-diagnostic cytology reassuring because no malignant cells were seen.
Using vascularity alone to label a lesion malignant or benign.
Forgetting iodinated contrast implications before planned radioiodine or in active autonomy.
Losing ownership of an incidental nodule between radiology, primary care and the MDT.
Your practice draft is saved in this browser.
An adult has a 2 cm thyroid nodule and suppressed TSH with normal free T4. Before routine aspiration, which next investigation most directly establishes whether the nodule is autonomous?
National guidance is shown before implementation-dependent detail. Typical adult dose examples remain subject to patient factors, contraindications and the live BNF or specialist protocol. Source check completed 27 Aug 2026; clinical approval remains outstanding.
Editorial contact: Doctor’s Passport editorial team. Source-check date is separate from clinical approval. Report a content problem · Content changes
Do not prescribe TSH-suppressive doses for an ordinary benign nodule. Cancer-specific suppression targets belong to specialist oncology follow-up and require rhythm and bone-risk review.